DUBAI, United Arab Emirates, Jan. 31, 2023 (GLOBE NEWSWIRE) -- A recent report published by Future Market Insights expects the mucinoses management market to expand at a CAGR of 19.5% during the 2023 to 2033 forecast period. As of 2023, the market is slated to reach a valuation of US$ 112.81 million. The mucinoses management market is expected to grow as a consequence of various variables impacting the healthcare industry, such as increased government funding for research and development, as well as significant changes implemented into the system to enable various health specialists to concentrate not only on providing sufficient volume but also on ensuring medical providers do not stymie the level of service. In 2017, the EU government spent USD 1221 billion on healthcare, accounting for approximately 7.1% of GDP.
Enhanced occurrences of head and neck cancer will be a major driving factor for the North American severe oral mucositis industry to expand in the years ahead. The prominent competitors in the United States are focusing on fundraising to supplement studies and development for managing severe oral mucositis induced by radiation therapy and chemotherapy in cancer patients.
Request Sample@ https://www.futuremarketinsights.com/reports/sample/rep-gb-16543
As a result of this factor, North America is expected to see market growth. The growth of Asia Pacific can be attributed to government programs that assist orphan ailment patients. For example, the Indian government directed federal and state governments in July 2022 to ensure that healthcare programs evolved to treat patients suffering from orphan diseases.
Key Takeaways from the Market Study
- From 2018 to 2022, sales increased significantly, with an 18% CAGR.
- In the United States, patients must pay an additional US$ 3,700 per loop for chemotherapeutic-induced oral mucositis.
- In 2021, the severe oral mucositis market in the United States is expected to be worth US$ 79 million.
- By 2033, the global mucinoses management market is expected to be worth US$ 669.95 million by 2033.
- According to FMI, the European Mucinoses Management market will grow at a 17.1% value CAGR by 2033.
“The proactive approaches premised on ground-breaking initiatives to introduce innovative SMA medicines to resolve unmet medical requirements in rare disease therapeutics is expected to propel industry growth,” says an FMI analyst.
Key Market Players
GSK plc, Almirall, S.A, Merck & Co., Inc, Bausch Health, Sandoz International GmbH, Pfizer Inc, AstraZeneca, Sanofi, Alencure Biotech, and Divine Laboratories are key players in the Mucinoses Management market. The following are some of the most recent developments by major manufacturers.
In July 2021, AstraZeneca paid US$ 13.3 billion for acquiring Alexion Pharmaceuticals, Inc. This acquisition strengthens the corporation's rare disorder product portfolio and provides significant opportunities for expansion.
- In June 2022, Pfizer acquired ReViral, a privately held clinical-stage biotech company. The acquisition will demonstrate the organization's approach to progressing and innovating science through in-house competence as well as the partnership with renowned, revolutionary companies in order to deliver innovative significant developments to patient populations afflicted by serious contagious diseases such as mucinoses.
View Complete Report@ https://www.futuremarketinsights.com/reports/mucinoses-management-market
Key Segments Profiled in the Mucinoses Management Market Industry Survey
By Drug Class:
- Topical Corticosteroids
- Corticosteroid Injections
- Oral Antibiotics
By Route of Administration:
- Oral
- Intralesional
- Topical
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Others
By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Ask an Analyst@ https://www.futuremarketinsights.com/ask-question/rep-gb-16543
More Valuable Insights Available
Future Market Insights offers an unbiased analysis of the global mucinoses management market, providing historical data for 2018 to 2022 and forecast statistics from 2023 to 2033.
To understand opportunities in the mucinoses management market, the market is segmented on the basis of Type (Topical Corticosteroids, Corticosteroid Injections, Oral Antibiotics), Material (Oral, Intralesional, Topical), Application (Neurology, Cardiology, Urology, Oncology, Peripheral Vascular Disease, and Other), and By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) , across five major regions (North America, Latin America, Europe, Asia Pacific and Middle East & Africa).
Table of Content
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
Buy Now@ https://www.futuremarketinsights.com/checkout/16543
About the Healthcare Division at Future Market Insights
The healthcare team at Future Market Insights offers expert analysis, time efficient research, and strategic recommendations with an objective to provide authentic insights and accurate results to help clients worldwide. With a repertoire of over 100+ reports and 1 million+ data points, the team has been analyzing the industry lucidly in 50+ countries for over a decade. The team provides a brief analysis on key trends including competitive landscape, profit margin, and research development efforts.
Have a Look at Related Reports of Healthcare domain
Chronic Disease Management Market Size: The global chronic disease management market garnered a value of US$ 4,315.3 Million in 2022 and is expected to accumulate a value of US$ 17,267.6 Million by 2032 registering a CAGR of 13.4% during the forecast period.
Lung Disease Therapeutics Market Share: The global lung disease therapeutics market garnered a market value of US$ 79,833.6 Million in 2022 and is expected to accumulate a market value of US$ 145,960.2 Million by registering a CAGR of 6.21% in the forecast period 2022-2032.
Catheter-Directed Thrombolysis Market Overview: The global catheter-directed thrombolysis market is valued at US$ 432.0 Million in 2022. The market is likely to grow at a CAGR of 5.9% and is anticipated to be valued at US$ 814.0 Million by 2032.
Staphylococcus Aureus Testing Market Demand: The staphylococcus aureus testing market is likely to cross the estimated market value of US$ 6.66 Billion by 2032, while it thrives in the global market at a lower CAGR of 4.9% (2022-2032). The market holds a revenue of US$ 3.94 Billion in 2022.
COPD Therapeutics Market Growth: The global COPD therapeutics market garnered a market value of US$ 11,668.8 Million in 2022 and is expected to accumulate a market value of US$ 20,127.7 Million by 2032, registering a CAGR of 5.1% over the forecast period.
About Future Market Insights (FMI)
Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai and has delivery centers in the UK, U.S., and India. FMI's latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.
Contact Us:
Future Market Insights, Inc.
1602-6 Jumeirah Bay X2 Tower,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
LinkedIn| Twitter| Blogs | YouTube
For Sales Enquiries: sales@futuremarketinsights.com
